Two studies were conducted on non-diabetic subjects and Phase 3.
Pharmachem Laboratories (Kearny, NJ) has announced the results of two studies on its Phase 3 Sugar Controller, showing that the ingredient can effectively reduce blood glucose and insulin after sugar intake.
Phase 3 Sugar Controller is a combination of a proprietary, patent-pending L-Arabinose and a patented form of chromium intended to help in the management of diabetes and obesity.
In a pilot study on 20 healthy non-diabetic subjects, taking Phase 3 with 70 grams of sucrose resulted in an average 31% reduction of blood glucose and a 32% reduction of insulin.
In a clinical trial on 50 healthy non-diabetic subjects, the same assignment led to an average 24.3% reduction of blood glucose and a 28.2% reduction of insulin.
Phase 3 Sugar Controller is part of the company’s three-phase process for diet management, which also includes Phase 1 Hunger Controller (for satiety) and Phase 2 Carb Controller (to reduce absorption of starch carbohydrates up to 66%).
No adverse effects were reported after 30 days of supplementation with Phase 3.
For more information, visit the company here.
WIN to host networking event and partner on education session at SupplySide East 2024
April 2nd 2024At this year’s SupplySide East, taking place on April 16 and 17 in Secaucus, NJ, Women in Nutraceuticals (WIN) will be hosting a networking event and partnering on an education session titled “Substantiating Products for Women – Building Trust Through Science.”